alexa
Reach Us +441414719275
Plasma Tenofovir Concentrations and Proximal Tubular Dysfunction in HIV-Infected Adults Receiving Tenofovir in Thailand | OMICS International | Abstract
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article

Plasma Tenofovir Concentrations and Proximal Tubular Dysfunction in HIV-Infected Adults Receiving Tenofovir in Thailand

Anchalee Avihingsanon1,2*, Jiratchaya Sophonphan1, Narukjaporn Thammajaruk1, Prachya Chaihong1, David Burger3, Tim R Cressey4,5, Reshmie A Ramautarsing1,6, Kearkiat Praditornsilpa7, Yingyos Avihingsanon7, Kiat Ruxrungtham1,2 and HIV-NAT 114 study team

1HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Pathumwan, Bangkok, Thailand

2Division of Allergy and Immunology, Faculty of Medicine, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok, Thailand

3Radboud Institute for Health Sciences (RIHS), Post 148 RIHS, PO box 9101, 6500 HB Nijmegen, The Netherlands

4Program for HIV Prevention and Treatment (PHPT)/IRD Unité 174, Faculty of Associated Medical Sciences, 187/10, Changklan Rd., Changklan, Muang, Chiang Mai, Thailand

5Harvard School of Public Health, Bldg 2, Flr 4, Rm 424, 655 Huntington Ave, Boston, MA, USA

6Amsterdam Institute for Global Health and Development, Academic Medical Center, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, the Netherlands

7Division of Nephrology, Faculty of Medicine, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok, Thailand

*Corresponding Author:
Anchalee Avihingsanon
HIV-NAT, Thai Red Cross AIDS Research Centre
104 Ratchadamri Road, Pathumwan
Bangkok, Thailand 10330
Tel: +66 2 255 7335
Fax: +66 2 252 5779
E-mail: [email protected], [email protected]

Received date: March 18, 2014; Accepted date: June 22, 2015; Published date: July 03, 2015

Citation: Avihingsanon A, Sophonphan J, Thammajaruk N, Chaihong P, Burger D, et al. (2015) Plasma Tenofovir Concentrations and Proximal Tubular Dysfunction in HIV-Infected Adults Receiving Tenofovir in Thailand. J AIDS Clin Res 6:477. doi:10.4172/2155-6113.1000477

Copyright: © 2015 Avihingsanon A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: HIV-infected Asians may be at risk for tenofovir toxicity due to their relatively low body weight (BW). We assessed the prevalence of proximal tubular dysfunction (PRTD) and risk associated with PRTD in HIV-infected adults receiving tenofovir in Thailand.

Methods: A cross-sectional study in HIV-infected adults (≥ 18years) treated with tenofovir for >1 year. Twenty-fourhour urine samples were collected to assess PRTD. PRTD was defined as the presence of >2 of the following criteria: hyper-phosphaturia (total excretion of phosphate >1200 mg/day or renal tubular reabsorption of phosphate (TmP/ GFR) < 2.6 mg/dl), hyper-uricosuria (FE of uric acid >15%), or non-diabetic glucosuria. Mid-dose tenofovir plasma concentrations were determined and concentrations >160 ng/mL were used as a cut-off for assessing risk of PRTD.

Results: 351 subjects (52% males) with median age of 40.2 years, BW of 58.9 kg, and duration of tenofovir treatment 4.7 years were included. 93% had a HIV-1 RNA <50 copies/mL and 7% were co-infected with HCV. Fiftyfour (15.4%) patients were diagnosed with PRTD. In a multivariate analysis, only a mid-dose tenofovir concentration >160ng/mL was associated with PRTD [odds ratio: OR 2.02 (95% CI 1.13-3.66)]; 32 of 54 (59.2%) with PRTD had a tenofovir concentration >160 ng/ml; versus 124 of 297 patients (41.7%) without PRTD (p = 0.02). Predictors of a tenofovir concentration >160ng/mL were BW<55 kg [OR2.32 (95% CI 1.45-3.68)], chronic HCV [OR 2.64 (95% CI 1.13-6.17)], eGFR<90 mL/min/1.73m2 [OR 2.66 (95% CI 1.64-4.31)], lopinavir/ritonavir [OR 2.47 (95% CI 1.32-4.6)] and PRTD [OR 2.08(95% CI 1.10-3.92)].

Conclusion: Mid-dose tenofovir concentrations >160 ng/mL were independently associated with PRTD. Tubular function should be closely monitored in patients using tenofovir with BW<55 kg, lopinavir/ritonavir use, chronic hepatitis C, or low eGFR.

Keywords

Top